Harnessing the Power of Complement System-Based Therapeutics -

Name: Harnessing the Power of Complement System-Based Therapeutics to Tackle Geographic Atrophy
Uploaded: 2022-04-05T04:00:00+00:00
Duration: 1 h 13 s
Description: As complement system-based therapies are poised to complete pivotal trials and possibly progress to FDA approval in the near future, clinicians who care fo

Media formats available:

Details

Presenters

Overview
As complement system-based therapies are poised to complete pivotal trials and possibly progress to FDA approval in the near future, clinicians who care for patients with GA must expand their knowledge of GA prevalence, pathogenesis, and the mechanism of action of complement system-based pipeline candidates.
Tune in for an informative on-demand CME webinar featuring Program Chair Carl Regillo, MD, along with Caroline Baumal, MD, and David Lally, MD. The experts discuss these topics and more aimed at improving care of patients with GA.
This activity is supported by an unrestricted educational grant from Iveric Bio.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize the prevalence of advanced AMD, including nAMD and GA
- Explain the pathogenesis of GA
- Interpret the role of the complement system in GA development, with a particular focus on complement factors 3 and 5 (C3 and C5)
- Review pipeline candidates under investigation for the treatment of GA
Accreditation
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Carl D. Regillo, MD, FACS
Chief, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Retina Surgeon
Mid Atlantic Retina
Philadelphia, PA

Caroline R. Baumal, MD
Professor of Ophthalmology
New England Eye Center
Tufts University School of Medicine
Boston, MA

David R. Lally, MD
Retina Research Institute at New England Retina Consultants
Assistant Professor
University of Massachusetts
Springfield, MA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Carl D. Regillo, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Allergan, Annexon, Apellis, Clearside, EyePoint Pharmaceuticals, Genentech, Graybug, Iveric Bio, Kodiac, NGM, Novartis, and Regenxbio. Grant/Research Support: Adverum Biotechnologies, Allergan, Annexon, Apellis, Genentech, Graybug, Iveric Bio, Kodiac, NGM, Novartis, Opthea, Regeneron, and Regenxbio.
Caroline R. Baumal, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Apellis, Genentech, Novartis, and Ora. Speaker's Bureau: Carl Zeiss Meditic and Regeneron Pharmaceuticals.
David R. Lally, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alimera, Allergan, Annexon, Apellis, Eyepoint, Genentech, Novartis, Ocuphire, Laboratories Thea, and Roche. Grant/Research Support: Annexon, Apellis, Chengdu Kanghong, Emmes Corporation, Eyepoint, Neurotech, Notal Vision, Novartis, Kodiak Biosciences, Ocuphire, Opthea, Oxurion, and Stealth Biotherapeutics. Speakers Bureau: Alimera, Allergan, Annexon, Apellis, Genentech, and Novartis. Shareholder: Ocuphire.
The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Iveric Bio.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/05/2022
Expiration Date: 04/05/2023

Carl D. Regillo, MD

Guest

Caroline R. Baumal, MD

Guest

David R. Lally, MD

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
CME/CE
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
Yewlin E. Chee, MD; Camila Ventura MD, PhD
1.50 credits
- Yewlin E. Chee, MD
- Camila Ventura MD, PhD
- Edward Wood, MD
- Tony Capone Jr, MD
- Katherine E. Talcott, MD
- Nassim Abreu, MD
1.50 credits
TKI: The New TKO for Retinal Diseases
TKI: The New TKO for Retinal Diseases
MinuteCE®
TKI: The New TKO for Retinal Diseases
Christina Y. Weng, MD, MBA, FASRS; Katherine E. Talcott, MD
0.75 program credits
- Christina Y. Weng, MD, MBA, FASRS
- Katherine E. Talcott, MD
0.75 program credits
To Implant or to Inject?
To Implant or to Inject?
MinuteCE®
To Implant or to Inject?
Katherine E. Talcott, MD; Roger A. Goldberg, MD, MBA
0.75 program credits
- Katherine E. Talcott, MD
- Roger A. Goldberg, MD, MBA
0.75 program credits
Who Needs a TKI? Identifying the Right Candidates
Who Needs a TKI? Identifying the Right Candidates
MinuteCE®
Who Needs a TKI? Identifying the Right Candidates
Roger A. Goldberg, MD, MBA; Christina Y. Weng, MD, MBA, FASRS
0.75 program credits
- Roger A. Goldberg, MD, MBA
- Christina Y. Weng, MD, MBA, FASRS
0.75 program credits

Harnessing the Power of Complement System-Based Therapeutics to Tackle Geographic Atrophy

Recommended

Title